S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.54 (+1.37%)
MSFT   208.27 (-1.98%)
FB   262.71 (-2.13%)
GOOGL   1,495.93 (-0.16%)
AMZN   3,148.16 (-0.61%)
NVDA   446.65 (-0.30%)
CGC   17.78 (+6.92%)
BABA   248.13 (-1.57%)
TSLA   1,413.60 (-2.69%)
GE   6.67 (+4.22%)
MU   49.08 (+0.68%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.23 (-0.39%)
GILD   68.55 (-1.15%)
NFLX   483.38 (-2.29%)
DIS   129.05 (-0.68%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.54 (+1.37%)
MSFT   208.27 (-1.98%)
FB   262.71 (-2.13%)
GOOGL   1,495.93 (-0.16%)
AMZN   3,148.16 (-0.61%)
NVDA   446.65 (-0.30%)
CGC   17.78 (+6.92%)
BABA   248.13 (-1.57%)
TSLA   1,413.60 (-2.69%)
GE   6.67 (+4.22%)
MU   49.08 (+0.68%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.23 (-0.39%)
GILD   68.55 (-1.15%)
NFLX   483.38 (-2.29%)
DIS   129.05 (-0.68%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.54 (+1.37%)
MSFT   208.27 (-1.98%)
FB   262.71 (-2.13%)
GOOGL   1,495.93 (-0.16%)
AMZN   3,148.16 (-0.61%)
NVDA   446.65 (-0.30%)
CGC   17.78 (+6.92%)
BABA   248.13 (-1.57%)
TSLA   1,413.60 (-2.69%)
GE   6.67 (+4.22%)
MU   49.08 (+0.68%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.23 (-0.39%)
GILD   68.55 (-1.15%)
NFLX   483.38 (-2.29%)
DIS   129.05 (-0.68%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.54 (+1.37%)
MSFT   208.27 (-1.98%)
FB   262.71 (-2.13%)
GOOGL   1,495.93 (-0.16%)
AMZN   3,148.16 (-0.61%)
NVDA   446.65 (-0.30%)
CGC   17.78 (+6.92%)
BABA   248.13 (-1.57%)
TSLA   1,413.60 (-2.69%)
GE   6.67 (+4.22%)
MU   49.08 (+0.68%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.23 (-0.39%)
GILD   68.55 (-1.15%)
NFLX   483.38 (-2.29%)
DIS   129.05 (-0.68%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
Log in

NASDAQ:OPKOpko Health Stock Price, Forecast & News

$5.46
-0.17 (-3.02 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.39
Now: $5.46
$5.70
50-Day Range
$2.38
MA: $4.17
$5.96
52-Week Range
$1.12
Now: $5.46
$6.47
Volume9.45 million shs
Average Volume15.01 million shs
Market Capitalization$3.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.46
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's Pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator for benign prostatic hyperplasia, and other urologic and metabolic conditions; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase II trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection in Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Read More
Opko Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.98 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:OPK
CUSIP68375N10
Phone305-575-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$901.90 million
Book Value$2.43 per share

Profitability

Net Income$-314,920,000.00

Miscellaneous

Employees6,096
Market Cap$3.66 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$5.46
-0.17 (-3.02 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPK News and Ratings via Email

Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Opko Health (NASDAQ:OPK) Frequently Asked Questions

How has Opko Health's stock been impacted by COVID-19 (Coronavirus)?

Opko Health's stock was trading at $1.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OPK shares have increased by 223.1% and is now trading at $5.46.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Opko Health?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Opko Health
.

When is Opko Health's next earnings date?

Opko Health is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Opko Health
.

How were Opko Health's earnings last quarter?

Opko Health Inc. (NASDAQ:OPK) announced its earnings results on Thursday, July, 30th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.12. The biotechnology company earned $301.20 million during the quarter, compared to analysts' expectations of $234.57 million. Opko Health had a negative net margin of 20.69% and a negative return on equity of 7.96%.
View Opko Health's earnings history
.

What price target have analysts set for OPK?

3 Wall Street analysts have issued twelve-month target prices for Opko Health's stock. Their forecasts range from $2.50 to $10.00. On average, they anticipate Opko Health's share price to reach $5.50 in the next year. This suggests a possible upside of 0.7% from the stock's current price.
View analysts' price targets for Opko Health
.

What are Wall Street analysts saying about Opko Health stock?

Here are some recent quotes from research analysts about Opko Health stock:
  • 1. According to Zacks Investment Research, "OPKO Health has gained significantly from RAYALDEE contribution in recent times. Further, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 18,800 tests registered in the second quarter. These apart, the company’s clinical development programs look promising with a robust pipeline of candidates. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. However, the company’s gross margin is under pressure at the moment. Moreover, the company faces cutthroat competition in the MedTech space. Sluggishness in the Services revenue segment remains a concern. OPKO Health underperformed its industry in a year’s time." (10/18/2019)
  • 2. Barrington Research analysts commented, "We continue to rate OPK shares an OUTPERFORM and our price target remains $4. That said, if the company were to receive a strong data readout from its Phase III trial for hGH‐CTP within the next few months, we suspect that shares would rally meaningfully from current levels and that investor sentiment could swing positive for the first time in over four years. We arrive at our price target via a DCF methodology. It is important to note that the company still has many “shots on goal” within its current commercial portfolio and product development pipeline." (9/12/2019)

Has Opko Health been receiving favorable news coverage?

Headlines about OPK stock have trended very positive on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Opko Health earned a news impact score of 3.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Opko Health
.

Are investors shorting Opko Health?

Opko Health saw a increase in short interest in July. As of July 31st, there was short interest totaling 137,170,000 shares, an increase of 5.9% from the July 15th total of 129,490,000 shares. Based on an average trading volume of 16,510,000 shares, the short-interest ratio is presently 8.3 days. Approximately 34.0% of the shares of the stock are short sold.
View Opko Health's Short Interest
.

Who are some of Opko Health's key competitors?

What other stocks do shareholders of Opko Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), bluebird bio (BLUE), Gray Television (GTN), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Allergan (AGN), AT&T (T) and Alibaba Group (BABA).

Who are Opko Health's key executives?

Opko Health's management team includes the following people:
  • Dr. Phillip Frost, Chairman & CEO (Age 83)
  • Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)
  • Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)
  • Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)
  • Ms. Kate Inman, Gen. Counsel & Sec. (Age 46)

What is Opko Health's stock symbol?

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

Who are Opko Health's major shareholders?

Opko Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Swiss National Bank (0.14%), Principal Financial Group Inc. (0.09%), UBS Group AG (0.06%), Rafferty Asset Management LLC (0.06%), Cambridge Investment Research Advisors Inc. (0.05%) and Strs Ohio (0.04%). Company insiders that own Opko Health stock include Adam Logal, Anthony J Japour, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin.
View institutional ownership trends for Opko Health
.

Which institutional investors are selling Opko Health stock?

OPK stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, SG Americas Securities LLC, Cambridge Investment Research Advisors Inc., Strs Ohio, Dupont Capital Management Corp, and Janney Montgomery Scott LLC.
View insider buying and selling activity for Opko Health
.

Which institutional investors are buying Opko Health stock?

OPK stock was purchased by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Rafferty Asset Management LLC, Swiss National Bank, AE Wealth Management LLC, Creative Planning, Virtu Financial LLC, Envestnet Asset Management Inc., and WINTON GROUP Ltd. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Anthony J Japour, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel, and Steven D Rubin.
View insider buying and selling activity for Opko Health
.

How do I buy shares of Opko Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Opko Health's stock price today?

One share of OPK stock can currently be purchased for approximately $5.46.

How big of a company is Opko Health?

Opko Health has a market capitalization of $3.66 billion and generates $901.90 million in revenue each year. The biotechnology company earns $-314,920,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. Opko Health employs 6,096 workers across the globe.

What is Opko Health's official website?

The official website for Opko Health is www.opko.com.

How can I contact Opko Health?

Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.